Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Inventory (2016 - 2025)

Historic Inventory for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to $3.2 billion.

  • Teva Pharmaceutical Industries' Inventory rose 572.0% to $3.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.2 billion, marking a year-over-year increase of 572.0%. This contributed to the annual value of $3.2 billion for FY2025, which is 572.0% up from last year.
  • Teva Pharmaceutical Industries' Inventory amounted to $3.2 billion in Q4 2025, which was up 572.0% from $3.3 billion recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Inventory ranged from a high of $4.4 billion in Q1 2021 and a low of -$147.0 million during Q4 2023
  • In the last 5 years, Teva Pharmaceutical Industries' Inventory had a median value of $3.9 billion in 2024 and averaged $3.6 billion.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Inventory tumbled by 10383.51% in 2023, and later surged by 214557.82% in 2024.
  • Teva Pharmaceutical Industries' Inventory (Quarter) stood at $3.8 billion in 2021, then grew by 0.39% to $3.8 billion in 2022, then tumbled by 103.84% to -$147.0 million in 2023, then surged by 2145.58% to $3.0 billion in 2024, then rose by 5.72% to $3.2 billion in 2025.
  • Its last three reported values are $3.2 billion in Q4 2025, $3.3 billion for Q3 2025, and $3.5 billion during Q2 2025.